{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"71.9","value":"2423"},{"groupId":"OG001","spread":"55.7","value":"4397"}]}],"title":"Part B: AUC0-t of DZD9008"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"125.2","value":"200.4"},{"groupId":"OG001","spread":"69.9","value":"448.5"}]}],"title":"Part B: AUC0-t of DZ0753"}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"description":"Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear up/log down rule.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized at a 1:1 ratio to receive sunvozertinib 200 mg once daily continuously.","id":"OG000","title":"Part B Dose Extension Cohort 1: EGFR exon20ins, Previously Treated; Sunvozertinib 200 mg"},{"description":"Patients with EGFR exon20ins, previously treated with at least one line of systemic therapy.\n\nPatients were randomized at a 1:1 ratio to receive sunvozertinib 300 mg once daily continuously.","id":"OG001","title":"Part B Dose Extension Cohort 2: EGFR exon20ins, Previously Treated; Sunvozertinib 300 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All dosed participants who have at least one measurable plasma concentration of DZD9008 post dose with no protocol deviations or adverse event thought to impact the analysis of the PK data.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: 0 (predose) up to 24 hours","title":"Part B: Area Under the Plasma Concentration-time Curve From Zero to the Last Measurable Concentration (AUC0-t) of DZD9008 and DZ0753.","type":"SECONDARY","unitOfMeasure":"h*ng/mL"}